The presentation focuses on atropisomerism, a type of stereoisomerism arising from restricted rotation around a bond axis due to steric hindrance or electronic factors, with applications in pharmaceutical compounds like KRAS inhibitors for lung cancer treatment. It covers the definition, energy of activation, nomenclature for assigning configurations, and catalyst-controlled stereoselective synthesis, emphasizing the time-dependent chirality and its potential impact if not properly managed. The content includes references to key studies and highlights ongoing challenges in achieving high enantiomeric excess in atropisomer-selective oxidative coupling reactions.